New drug duo takes on recurrent brain cancer

NCT ID NCT07678684

Recruiting now Disease control Sponsor: HighField Biopharmaceuticals Corporation Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether an investigational drug called HF1K16, when combined with the approved drug bevacizumab, can help people with recurrent or progressive glioma—a type of brain tumor. The trial enrolls about 30 adults whose tumors have returned or worsened after prior treatment. Researchers will monitor tumor response, side effects, and how long participants live without the disease getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HF1K16 combined with bevacizumab
What this could lead to: If successful, this combination could offer a new treatment option for people with recurrent or progressive glioma who have run out of standard therapies.
What could go wrong: This is an early Phase 2 study with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to slow tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT GLIOMA

Contacts and locations

Locations

Huashan Hospital Affiliated to Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.